{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:02:24Z","timestamp":1789956144387,"version":"4.0.1"},"reference-count":31,"publisher":"Tsinghua University Press","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Sacubitril\/Allisartan, a novel angiotensin receptor-neprilysin inhibitor, has demonstrated antihypertensive efficacy in patients with hypertension. Its effects in the elderly patients, who often present with increased arterial stiffness and comorbidities, remain less understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We performed analysis of data from a randomized clinical trial that compared the blood pressure-lowering effect at 12 weeks of treatment with sacubitril\/allisartan (240 mg\/d or 480 mg\/d) and olmesartan (20 mg\/d). Eligible patients with mild-to-moderate hypertension and aged 65\u201375 years were included in the analysis. The primary outcome was change in clinic and 24-hour ambulatory blood pressure from baseline to week 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of the 1197 randomized patients, 338 elderly patients (41.5%) (mean age: 67.9 \u00b1 2.3 years, 49.9% male) were included in this analysis. Baseline characteristics were comparable among treatment groups. At 12 weeks, least square mean (\u00b1 standard error) changes from baseline in clinic systolic\/diastolic blood pressure in the sacubitril\/allisartan (240 mg\/d or 480 mg\/d) group and the olmesartan (20 mg\/d) group were \u221224.0 \u00b1 1.6\/\u22125.7 \u00b1 0.9 mmHg, \u221226.2 \u00b1 1.6\/\u22126.5 \u00b1 0.9 mmHg, and \u221221.5 \u00b1 1.6\/\u22126.3 \u00b1 0.9 mmHg, respectively. Greater reductions were also observed with sacubitril\/allisartan (480 mg) compared with olmesartan (20 mg) in 24-hour, daytime and nighttime systolic blood pressure (all P-values &lt; 0.05). The reductions in ambulatory blood pressure were dose-dependent (P = 0.007), and significantly greater with sacubitril\/allisartan (480 mg) compared with olmesartan (20 mg) for nighttime blood pressure [\u221217.5 \u00b1 1.8\/\u22128.1 \u00b1 1.0 mmHg, with a difference of \u221210.9 mmHg (\u221216.1 to \u22125.8, P &lt; 0.0001) for systolic blood pressure and \u22124.5 mmHg (\u22127.3 to \u22121.8, P = 0.002) for diastolic blood pressure].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In elderly patients with hypertension, sacubitril\/allisartan provided dose-dependent greater blood pressure reductions compared with olmesartan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.26599\/1671-5411.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:19:24Z","timestamp":1789953564000},"page":"505-514","source":"Crossref","is-referenced-by-count":0,"title":["Blood pressure lowering efficacy of sacubitril\/allisartan versus olmesartan in elderly Chinese hypertensive patients"],"prefix":"10.26599","volume":"23","author":[{"given":"Wei","family":"ZHANG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"YAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"GE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hong","family":"LU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"XU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Chao","family":"SUN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Mei","family":"MU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Chen","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Nan","family":"ZHOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Guang","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11138","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41569-022-00829-z","article-title":"Hypertension in China: epidemiology and treatment initiatives","volume":"20","author":"JG Wang","year":"2023","unstructured":"JG Wang. Hypertension in China: epidemiology and treatment initiatives. 2023, 20: 531-545.","journal-title":"Nat Rev Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.117.032380","article-title":"Status of hypertension in China: results from the China Hypertension Survey, 2012-2015","volume":"137","author":"Z Wang","year":"2018","unstructured":"Z Wang. Status of hypertension in China: results from the China Hypertension Survey, 2012-2015. 2018, 137: 2344-2356.","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa1803180","article-title":"Effect of systolic and diastolic blood pressure on cardiovascular outcomes","volume":"381","author":"AC Flint","year":"2019","unstructured":"AC Flint. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. 2019, 381: 243-251.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1. 25 million people","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"E Rapsomaniki. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1. 25 million people. 2014, 383: 1899-1911.","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/eurheartj\/ehp109","article-title":"Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis","volume":"30","author":"S Bangalore","year":"2009","unstructured":"S Bangalore. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. 2009, 30: 1395-1401.","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jacc.2024.11.007","article-title":"Systolic blood pressure and pulse pressure in heart failure: pooled participant-level analysis of 4 trials","volume":"85","author":"H Lu","year":"2025","unstructured":"H Lu. Systolic blood pressure and pulse pressure in heart failure: pooled participant-level analysis of 4 trials. 2025, 85: 710-722.","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41371-020-00407-1","article-title":"Salt sensitivity and hypertension","volume":"35","author":"O Balafa","year":"2021","unstructured":"O Balafa. Salt sensitivity and hypertension. 2021, 35: 184-192.","journal-title":"J Hum Hypertens"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/jch.13652","article-title":"Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: the HOPE Asia Network","volume":"21","author":"K Kario","year":"2019","unstructured":"K Kario. Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: the HOPE Asia Network. 2019, 21: 1250-1283.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3904\/kjim.2019.196","article-title":"Current status and therapeutic considerations of hypertension in the elderly","volume":"34","author":"JH Lee","year":"2019","unstructured":"JH Lee. Current status and therapeutic considerations of hypertension in the elderly. 2019, 34: 687-695.","journal-title":"Korean J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/13543784.2021.1985464","article-title":"A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers","volume":"31","author":"Y Hu","year":"2022","unstructured":"Y Hu. A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers. 2022, 31: 977-985.","journal-title":"Expert Opin Investig Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41440-023-01326-7","article-title":"Efficacy and safety of sacubitril\/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study","volume":"46","author":"J Zhang","year":"2023","unstructured":"J Zhang. Efficacy and safety of sacubitril\/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study. 2023, 46: 2024-2032.","journal-title":"Hypertens Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jacasi.2024.06.002","article-title":"Efficacy and safety of sacubitril\/allisartan for the treatment of primary hypertension","volume":"4","author":"W Zhang","year":"2024","unstructured":"W Zhang. Efficacy and safety of sacubitril\/allisartan for the treatment of primary hypertension. 2024, 4: 697-707.","journal-title":"JACC Asia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"O Vardeny","year":"2014","unstructured":"O Vardeny. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. 2014, 2: 663-670.","journal-title":"JACC Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jash.2015.11.012","article-title":"The two faces of hypertension: role of aortic stiffness","volume":"10","author":"H Smulyan","year":"2016","unstructured":"H Smulyan. The two faces of hypertension: role of aortic stiffness. 2016, 10: 175-183.","journal-title":"J Am Soc Hypertens"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jch.13437","article-title":"Efficacy and safety of sacubitril\/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study","volume":"21","author":"Y Huo","year":"2019","unstructured":"Y Huo. Efficacy and safety of sacubitril\/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study. 2019, 21: 67-76.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","article-title":"Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension","volume":"69","author":"TD Wang","year":"2017","unstructured":"TD Wang. Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. 2017, 69: 32-41.","journal-title":"Hypertension"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/hr.2014.169","article-title":"Systolic hypertension: an increasing clinical challenge in Asia","volume":"38","author":"JB Park","year":"2015","unstructured":"JB Park. Systolic hypertension: an increasing clinical challenge in Asia. 2015, 38: 227-236.","journal-title":"Hypertens Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jacc.2014.10.060","article-title":"Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study","volume":"65","author":"Y Yano","year":"2015","unstructured":"Y Yano. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. 2015, 65: 327-335.","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jacc.2009.09.061","article-title":"Pulse pressure amplification a mechanical biomarker of cardiovascular risk","volume":"55","author":"A Benetos","year":"2010","unstructured":"A Benetos. Pulse pressure amplification a mechanical biomarker of cardiovascular risk. 2010, 55: 1032-1037.","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study","volume":"69","author":"B Williams","year":"2017","unstructured":"B Williams. Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. 2017, 69: 411-420.","journal-title":"Hypertension"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/ajh\/hpx111","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) compared with olmesartan in elderly Asian patients (\u2265 65 years) with systolic hypertension","volume":"30","author":"O Supasyndh","year":"2017","unstructured":"O Supasyndh. Efficacy and safety of sacubitril\/valsartan (LCZ696) compared with olmesartan in elderly Asian patients (\u2265 65 years) with systolic hypertension. 2017, 30: 1163-1169.","journal-title":"Am J Hypertens"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e032641","DOI":"10.1161\/JAHA.123.032641","article-title":"Angiotensin receptor-neprilysin inhibition (sacubitril\/valsartan) reduces structural arterial stiffness in middle-aged mice","volume":"13","author":"IN Schellinger","year":"2024","unstructured":"IN Schellinger. Angiotensin receptor-neprilysin inhibition (sacubitril\/valsartan) reduces structural arterial stiffness in middle-aged mice. 2024, 13: e032641.","journal-title":"J Am Heart Assoc"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.ihj.2018.01.002","article-title":"Sacubitril\/valsartan: a novel angiotensin receptor-neprilysin inhibitor","volume":"70","author":"RR Dargad","year":"2018","unstructured":"RR Dargad. Sacubitril\/valsartan: a novel angiotensin receptor-neprilysin inhibitor. 2018, 70: S102-S110.","journal-title":"Indian Heart J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e48692","DOI":"10.7759\/cureus.48692","article-title":"Antihypertensive effects of sacubitril\/valsartan versus olmesartan: an updated systemic review and meta-analysis of randomized controlled trials","volume":"15","author":"R Raja","year":"2023","unstructured":"R Raja. Antihypertensive effects of sacubitril\/valsartan versus olmesartan: an updated systemic review and meta-analysis of randomized controlled trials. 2023, 15: e48692.","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/ehjcvp\/pvab030","article-title":"Renal protection in chronic heart failure: focus on sacubitril\/valsartan","volume":"7","author":"R Pontremoli","year":"2021","unstructured":"R Pontremoli. Renal protection in chronic heart failure: focus on sacubitril\/valsartan. 2021, 7: 445-452.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref26","first-page":"5473","article-title":"LCZ696 (sacubitril\/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD","volume":"9","author":"W Jing","year":"2017","unstructured":"W Jing. LCZ696 (sacubitril\/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. 2017, 9: 5473-5484.","journal-title":"Am J Transl Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"F Spannella","year":"2020","unstructured":"F Spannella. Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. 2020, 7: 3487-3496.","journal-title":"ESC Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"173444","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis","volume":"884","author":"H Kang","year":"2020","unstructured":"H Kang. Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis. 2020, 884: 173444.","journal-title":"Eur J Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41440-021-00819-7","article-title":"Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study","volume":"45","author":"H Rakugi","year":"2022","unstructured":"H Rakugi. Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. 2022, 45: 824-833.","journal-title":"Hypertens Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1355014","DOI":"10.3389\/fcvm.2024.1355014","article-title":"Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis","volume":"11","author":"F Zhao","year":"2024","unstructured":"F Zhao. Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis. 2024, 11: 1355014.","journal-title":"Front Cardiovasc Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/FJC.0000000000000485","article-title":"Efficacy and safety of crystalline valsartan\/sacubitril (LCZ696) compared with placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study","volume":"69","author":"JL Jr Izzo","year":"2017","unstructured":"JL Jr Izzo. Efficacy and safety of crystalline valsartan\/sacubitril (LCZ696) compared with placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study. 2017, 69: 374-381.","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:19:25Z","timestamp":1789953565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2026.08.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2026.08.002","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}